A Phase 2 Clinical Trial of Dichloroacetate in Plateau Phase Myeloma - DiCAM

This study is testing whether a drug called dichloroacetate (DCA) can suppress multiple myeloma — a type of blood cancer — when the cancer is in a stable, non-progressing phase called 'plateau phase.' DCA works differently from standard cancer treatments by targeting the way cancer cells produce energy. Participants take DCA capsules by mouth every day for 3 months. You may be eligible if: - You are 18 years of age or older - You have been diagnosed with multiple myeloma (plasma cell myeloma) - Your cancer is currently in 'plateau phase' — it has been neither progressing nor responding to treatment for at least 28 days since your last treatment change - Your cancer shows measurable levels in blood tests - You have a performance status that allows daily activities - Your doctor expects you to live more than 3 months You may NOT be eligible if: - You are unable to give informed consent - Your myeloma produces no measurable protein (non-secretory myeloma) - You have received active anti-myeloma treatment (other than maintenance therapy) within the last 16 weeks - You are pregnant or breastfeeding - You are unable to swallow capsules - You have had major surgery in the last 28 days - You have severe nerve problems (grade 3 or worse neuropathy, tremor, or ataxia) - You have known liver disease or abnormal liver function tests - You have significant kidney impairment - You have significant heart problems Talk to your doctor about whether this trial might be right for you.